Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMO: Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV
NCT04265950Phase 4Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2022
- Primary completion
- May 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 3
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Fred Hutchinson Cancer Center. Started Mar 2022; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04265950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265950.